乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-090 广东乐心医疗电子股份有限公司 关于调整部分募集资金投资项目内部投资结构并延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日 召开第五届董事会第四次会议，审议通过了《关于调整部分募集资金投资项目内 部投资结构并延期的议案》，同意公司调整募集资金投资项目（以下简称"募投 项目"）"智能血糖监测产品产业化建设项目"的内部投资结构并将该募投项目 延期。本次调整和延期不改变该募投项目的募集资金用途、实施主体以及投资总 额。上述事项在董事会审批范围内，无需提交公司股东会审议；保荐机构对上述 事项发表了核查意见。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意广东乐心医疗电子股份有限公司向特 定对象发行股票注册的批复》（证监许可[2020]3233 号）核准，并经深圳证券交易 所同意，公司以向特定对象发行股票的方式向 14 名特定投资者（对应 22 个证 ...

国泰海通证券股份有限公司 关于广东乐心医疗电子股份有限公司 调整部分募集资金投资项目内部投资结构并延期的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通""保荐机构"或"保荐 人"）作为广东乐心医疗电子股份有限公司（以下简称"乐心医疗""公司"或"发 行人"）向特定对象发行股票的持续督导保荐机构，根据《证券发行上市保荐业 务管理办法》《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管 指引第 13 号——保荐业务》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定， 对公司调整部分募集资金投资项目内部投资结构并延期事项进行核查，具体核查 情况如下： | 序号 | 项目名称 | 投资总额 | 拟使用募集资 | 调整后拟使用 | | --- | --- | --- | --- | --- | | | | | 金 | 募集资金 | | 1 | 健康智能手表生产线建设项目 | 15,892.32 | 15,892.32 | 15,892.32 | | 2 | 基于传感器应用的智能货架生产线建 设项目 | 16,045.04 | 1 ...

乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-089 广东乐心医疗电子股份有限公司 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 经审议，董事会同意公司根据实际情况调整募投项目"智能血糖监测产品产 业化建设项目"内部投资结构并将其延期，本次调整不涉及改变该募投项目实施 主体、实施地点、投资总额以及募集资金用途，本次延期系根据当前行业政策结 合该项目当前开展的实际情况而做出的审慎决策，不存在变相改变募集资金用途、 损害公司及股东利益的情形。 本议案已经公司第五届董事会审计委员会审议通过。 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 1、广东乐心医疗电子股份有限公司（以下简称"公司"）第五届董事会第 四次会议于 2025 年 8 月 27 日以电子邮件、电话、专人送达等方式通知全体董事， 经全体董事同意豁免本次会议通知时间要求，会议于 2025 年 8 月 29 日在公司会 议室以通讯方式召开。 2、本次会议应到董事 7 人，实到董事 7 人。会议 ...

Core Viewpoint - Leksin Medical primarily sources its raw materials domestically, with a minimal percentage imported from overseas, specifically the United States, which accounts for less than 1% of the total procurement [2]. Group 1 - The company responded to investor inquiries regarding the proportion of raw materials imported from the United States [2]. - The company emphasized that the majority of its raw materials are procured domestically, indicating a strong reliance on local supply chains [2].

Trading Information Summary - On August 20, 2025, the main funds of Lifeness Medical experienced a net outflow of 9.3686 million yuan, while speculative funds saw a net outflow of 5.4452 million yuan. In contrast, retail investors had a net inflow of 14.8138 million yuan [1][3]. Company Announcement Summary - Lifeness Medical announced a semi-annual equity distribution plan for 2025, stating that it will distribute a cash dividend of 1.30 yuan (including tax) for every 10 shares based on a total of 217,289,788 shares, amounting to a total cash dividend of 28,247,672.44 yuan. The record date for the distribution is set for August 25, 2025, and the ex-dividend date is August 26, 2025 [1][3]. - The company will not issue bonus shares or convert capital reserves into share capital, and the remaining undistributed profits will be carried forward to future years. Additionally, the company will adjust the exercise price of the 2024 stock option incentive plan [1].

Core Viewpoint - The company plans to distribute a cash dividend of RMB 1.30 per 10 shares (including tax) for the 2025 interim profit distribution, totaling RMB 28,247,672.44, with no stock dividends or capital reserve transfers [1][2][4]. Summary by Sections 1. Profit Distribution Plan - The company will distribute cash dividends based on a total share count of 217,289,788 shares, with a maximum cash dividend amount not exceeding the net profit attributable to shareholders for the corresponding period [2][4]. 2. Implementation Details - The cash dividend of RMB 1.30 per 10 shares will be distributed to all shareholders, with specific tax implications for different types of shareholders [2][3][4]. 3. Key Dates - The record date for the dividend distribution is set for August 25, 2025, and the ex-dividend date is August 26, 2025 [3][4]. 4. Eligible Shareholders - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the record date, excluding shares held in the company's repurchase account [4][5]. 5. Dividend Payment Method - Cash dividends will be directly credited to shareholders' accounts through their securities companies or other custodians [4][5]. 6. Adjustments and Future Implications - Following the dividend distribution, adjustments will be made to the exercise price of the 2024 stock option incentive plan in accordance with relevant regulations [6].

乐心医疗 2025 年公 证券代码：300562 证券简称：乐心医疗 公告编号：2025-088 广东乐心医疗电子股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、2025 年半年度权益分派方案为：以 217,289,788 股为基数，向全体股东 每 10 股派发现金人民币 1.30 元（含税），2025 年半年度拟分配现金股利合计人 民币 28,247,672.44 元。不送红股，不以资本公积转增股本；剩余未分配利润结 转至以后年度。若本次权益分配方案公告后至实施前，公司因股权激励行权、股 份回购等原因导致股本总额发生变化的，将按照分配比例不变的原则调整分配总 额。 注：根据相关规定，回购专户中的股份不得参与权益分派，目前公司回购专户持有公司 股份 912,200 股。因此，本次利润分配预案的股本基数 217,289,788 股 = 公司目前总股本 218,201,988 股－回购专户股份数量 912,200 股；下同。 乐心医疗 2025 年公 1、2025 年 4 月 18 日，公司召开 2 ...

Core Insights - Le Xin Medical (300562.SZ) reported a total operating revenue of 521 million yuan for the first half of 2025, an increase of 22.77 million yuan compared to the same period last year, marking a year-on-year growth of 4.57% [1] - The net profit attributable to shareholders reached 42.29 million yuan, up by 7.44 million yuan year-on-year, achieving a growth of 21.35% compared to the same period last year [1] - The net cash inflow from operating activities was 48.25 million yuan, an increase of 15.38 million yuan year-on-year, reflecting a growth of 46.80% [1] Financial Performance - The latest debt-to-asset ratio stands at 33.31%, a decrease of 1.64 percentage points from the previous quarter and a reduction of 2.67 percentage points compared to the same period last year [3] - The latest gross profit margin is 35.00% [3] - The return on equity (ROE) is 4.19%, an increase of 0.82 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.19 yuan, an increase of 0.03 yuan year-on-year, reflecting a growth of 21.03% [3] - The total asset turnover ratio is 0.35 times, an increase of 0.03 times year-on-year, marking a growth of 9.78% [3] - The inventory turnover ratio is 4.06 times, an increase of 0.58 times year-on-year, reflecting a growth of 16.74% [3] Shareholder Structure - The number of shareholders is 25,700, with the top ten shareholders holding a total of 78.08 million shares, accounting for 35.89% of the total share capital [3] - The largest shareholder is Pan Weichao, holding 30.71% of the shares [3]

Core Viewpoint - On August 18, a total of 19 listed companies had their restricted shares unlocked, with a total market value of approximately 32.581 billion yuan [1]. Group 1: Unlocking Details - The specific details of the restricted share unlocks are as follows: - **Sunshine Energy (000591)**: 314 million shares from A-share original shareholder allocation [2] - **Paislin (600215)**: 2.0375 million shares from equity incentive lock-up [2] - **Xin'ao Co. (600803)**: 253 million shares from A-share corporate allocation [2] - **Hualan Biological (301207)**: 459 million shares with extended lock-up period [2] - **Taihe New Materials (002254)**: 436,000 shares from equity incentive lock-up [2] - **Yinxi Technology (300221)**: 569,890 shares from equity incentive lock-up [2] - **Loxin Medical (300562)**: 110,000 shares from equity incentive lock-up [2] - **Bona Film (001330)**: 319 million shares from pre-issue lock-up [2] - **Yuanfei Pet (001222)**: 112 million shares from pre-issue lock-up [2] - **Kaige Precision Machinery (301338)**: 72.1 million shares from pre-issue lock-up [2] - **Dingjide (603255)**: 72.7914 million shares from pre-issue lock-up [2] - **Shangji Technology (301330)**: 18.515 million shares from pre-issue lock-up [2] - **Zhongchumai (688267)**: 83.3928 million shares [2] - **Luwei Optoelectronics (688401)**: 77.6214 million shares [2] - **Haohan Depth (688292)**: 10.8085 million shares [2] - **Huicheng Co. (688403)**: 259 million shares [2] - **Kaiweite (688693)**: 921,100 shares [2] - **Xinyu Ren (688573)**: 122,190 shares [2] - **Sinan Navigation (688592)**: 77,700 shares [2]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it indicates a positive trend in the pharmaceutical and biotechnology sector with a weekly increase of 3.08% [3][8]. Core Insights - The pharmaceutical and biotechnology sector outperformed the Wind All A index and the CSI 300 index during the week of August 11 to August 15, with notable gains in medical research outsourcing (7.77%), hospitals (5.59%), and medical consumables (4.47%) [3][8]. - The upcoming launch of the commercial insurance innovative drug directory is expected to activate the domestic high-end payment market for innovative drugs, with 121 drug names passing preliminary review [3][8]. - The World Conference on Lung Cancer (WCLC) will take place from September 6 to 9, showcasing significant research advancements in lung cancer, with domestic research playing an increasingly important role [3][8]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 3.08%, outperforming the Wind All A index (2.95%) and the CSI 300 index (2.37%) [3][8]. - Medical research outsourcing, hospitals, and medical consumables led the sector's gains, while offline pharmacies, blood products, and medical circulation experienced declines [3][8]. - Notable individual stock performances included Sino Medical (69.1%), Innovation Medical (51.5%), and Guangsheng Tang (40.7%) for gains, while *ST Suwu (-16.8%), ST Sansheng (-15.2%), and Nanhua Biological (-14.2%) faced significant losses [3][11]. Industry News and Key Company Announcements - The National Medical Insurance Administration announced the preliminary review of the 2025 National Basic Medical Insurance drug directory and the commercial insurance innovative drug directory [3][13]. - Novo Nordisk received accelerated FDA approval for its therapy Wegovy for treating non-alcoholic steatohepatitis (NASH) [3][13]. - Yunnan Baiyao approved a full acquisition of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million RMB to enhance its traditional Chinese medicine business [3][15]. - Insmed's DPP1 inhibitor Brensocatib received FDA approval for treating non-cystic fibrosis bronchiectasis [3][14].